Pages
Home
Investments
Transaction Advisory
Investment Research and Business Due Diligence
Contact Us
Thursday, June 6, 2013
Otsuka Pharmaceutical Submits New Drug Application in Japan for Tolvaptan for the Treatment of Autosomal Dominant Polycystic Kidney Disease (ADPKD)
Otsuka Pharmaceutical Co., Ltd. has filed an application with the Pharmaceutical and Medical Devices Agency in Japan (PMDA) to market its novel compound tolvaptan for the treatment of Autosomal Dominant Polycystic Kidney Disease (ADPKD). Phase III clinical trial results that form the basis of the regulatory filing were published in the New England Journal of Medicine in November 2012. In the Phase 3 trials,
involving 1,400 ADPKD patients from 15 countries,
Tolvaptan
demonstrated a statistically significant reduction in the rate of total kidney volum
e. The MHLW has designated tolvaptan as an Orphan Drug.
Enter your email address:
Delivered by
FeedBurner
No comments:
Post a Comment
Newer Post
Older Post
Home
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment